Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$84.27

-3.74 (-4.25%)

18:04
10/22/18
10/22
18:04
10/22/18
18:04

AbbVie reports 'positive' data from Phase 2b/3 study of upadacitinib

AbbVie announced positive results from U-ACHIEVE, an ongoing Phase 2b/3 dose-ranging study evaluating upadacitinib, an investigational JAK1-selective inhibitor, for induction and maintenance therapy in adult patients with moderately to severely active ulcerative colitis. After 8 weeks, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission and all ranked secondary endpoints. These clinical data, in addition to patient-reported outcomes data from the study, are being presented at United European Gastroenterology Week 2018 in Vienna, Austria. Upadacitinib is not approved by regulatory authorities and its safety and efficacy have not been established. The study showed that significantly more patients achieved clinical remission with upadacitinib (14/14/20 percent of patients in the 15/30/45 mg groups) compared to placebo (0 percent) at week 8.1 Additionally, key secondary endpoints were also achieved at week 8 across the upadacitinib 15/30/45 mg groups, including endoscopic improvement, clinical remission and clinical response. The upadacitinib 7.5 mg group did not meet the primary endpoint. These results are being presented October 22 during an oral presentation entitled "Efficacy and safety of upadacitinib as an induction therapy for patients with moderately to severely active ulcerative colitis: data from the phase 2b study U-ACHIEVE" from 2:12 - 2:24 p.m. CEST.

  • 02

    Nov

ABBV AbbVie
$84.27

-3.74 (-4.25%)

10/22/18
RHCO
10/22/18
NO CHANGE
Target $135
RHCO
Buy
AbbVie price target lowered to $135 from $157 at SunTrust
SunTrust analyst John Boris lowered his price target on AbbVie to $135 after his discussions with its management about the challenges coming from "Humira biosimilar discounts" in the E.U. The analyst notes that he is also lowering his FY19 revenue forecasts to $33.9B from $34.5B to reflect his updated lower HCV global market model and lower Mavyret sales from lower volumes. Boris also keeps his Buy rating on AbbVie longer term, citing potential benefits from the Imbruvica/Venclexta uptake/label expansion and any incremental M&A under incoming CFO Rob Michael.
10/19/18
FBCO
10/19/18
NO CHANGE
Target $85
FBCO
Underperform
AbbVie's 'surprise' CFO change raises more questions, says Credit Suisse
After AbbVie announced this morning that CFO Bill Chase will retire in mid-2019 and be replaced by the current Controller Robert Michael, Credit Suisse analyst Vamil Divan said he was "surprised" by the news for several reasons. He does not recall recent commentary from the company suggesting a CFO transition was in the works; he does not believe the Street had been expecting a CFO transition; the change is clearly happening at a sensitive time, given the launch of biosimilar versions of Humira in Europe this week and increasing questions around the mid-to-long term growth outlook for Humira in the U.S.; and this news was disclosed in an 8-K with no accompanying press release, Divan noted. While comments reinforcing the company's views on its longer-term outlook are "not required" in this case, they would have made Divan feel more comfortable that this was a well-planned transition, he added. The analyst keeps an Underperform rating and $85 price target on AbbVie shares, which are down 1% to $88.88.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.

TODAY'S FREE FLY STORIES

TEX

Terex

$35.29

-0.3 (-0.84%)

19:01
02/22/19
02/22
19:01
02/22/19
19:01
Hot Stocks
Terex to sell Demag Mobile Cranes business to Tadano for $215M enterprise value »

Terex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

CZR

Caesars

$9.05

-0.37 (-3.93%)

18:34
02/22/19
02/22
18:34
02/22/19
18:34
Hot Stocks
Canyon Partners: Caesars shareholders' value best served by open sale process »

Canyon Partners issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$20.85

0.17 (0.82%)

, BA

Boeing

$424.05

6.57 (1.57%)

18:11
02/22/19
02/22
18:11
02/22/19
18:11
Periodicals
Brazilian judge suspends Embraer-Boeing deal talks, Reuters reports »

A Brazilian judge…

ERJ

Embraer

$20.85

0.17 (0.82%)

BA

Boeing

$424.05

6.57 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 14

    Mar

  • 28

    May

BXG

Bluegreen Vacations

$14.47

0.55 (3.95%)

18:02
02/22/19
02/22
18:02
02/22/19
18:02
Earnings
Bluegreen Vacations reports Q4 EPS 27c, consensus 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

SM

SM Energy

$16.88

-0.13 (-0.76%)

17:57
02/22/19
02/22
17:57
02/22/19
17:57
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy's higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AN

AutoNation

$37.22

-1.15 (-3.00%)

17:47
02/22/19
02/22
17:47
02/22/19
17:47
Syndicate
Breaking Syndicate news story on AutoNation »

AutoNation files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

TSLA

Tesla

$294.60

3.42 (1.17%)

, NSANY

Nissan

$0.00

(0.00%)

17:42
02/22/19
02/22
17:42
02/22/19
17:42
Periodicals
Tesla's Model 3 was the highest-selling EV globally in 2018, Verge reports »

Tesla's (TSLA) Model…

TSLA

Tesla

$294.60

3.42 (1.17%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

FSFG

First Savings Financial Group

$51.33

0.22 (0.43%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Hot Stocks
First Savings Financial raises quarterly dividend to 16c per share from 15c »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$110.97

1.5 (1.37%)

17:31
02/22/19
02/22
17:31
02/22/19
17:31
Periodicals
Employees demand Microsoft cancel $480M U.S. Army contract, Reuters says »

Several Microsoft workers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 06

    Mar

  • 07

    Mar

  • 18

    Mar

ENT

Global Eagle

$2.66

(0.00%)

17:23
02/22/19
02/22
17:23
02/22/19
17:23
Hot Stocks
Global Eagle to cut workforce by roughly 15% »

As previously disclosed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:15
02/22/19
02/22
17:15
02/22/19
17:15
General news
Breaking General news story  »

New York Federal Reserve…

NOC

Northrop Grumman

$288.84

2.54 (0.89%)

17:13
02/22/19
02/22
17:13
02/22/19
17:13
Hot Stocks
Northrop Grumman exec Kalan sells 4,312 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYB

LyondellBasell

$89.14

0.63 (0.71%)

17:07
02/22/19
02/22
17:07
02/22/19
17:07
Syndicate
Breaking Syndicate news story on LyondellBasell »

LyondellBasell files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCCO

Technical Comm Corp

$2.76

0.17 (6.56%)

17:06
02/22/19
02/22
17:06
02/22/19
17:06
Hot Stocks
Technical Comm Corp to submit plan to regain compliance with Nasdaq by March 4 »

Technical Comm Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFU

InfuSystem

$4.15

0.04 (0.97%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
InfuSystem announces settlement of derivative lawsuit »

InfuSystem Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALU

Kaiser Aluminum

$108.22

-1.9 (-1.73%)

17:01
02/22/19
02/22
17:01
02/22/19
17:01
Hot Stocks
Kaiser Aluminum names Neal West as new CFO »

Kaiser Aluminum announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDR

Alder Biopharmaceuticals

$14.35

0.19 (1.34%)

17:00
02/22/19
02/22
17:00
02/22/19
17:00
Hot Stocks
Alder Biopharmaceuticals submits eptinezumab BLA to FDA »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

RF

Regions Financial

$16.24

-0.01 (-0.06%)

16:59
02/22/19
02/22
16:59
02/22/19
16:59
Syndicate
Breaking Syndicate news story on Regions Financial »

Regions Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

HL

Hecla Mining

$2.59

-0.145 (-5.31%)

16:58
02/22/19
02/22
16:58
02/22/19
16:58
Syndicate
Breaking Syndicate news story on Hecla Mining »

Hecla Mining files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

, CELG

Celgene

$89.15

0.54 (0.61%)

16:52
02/22/19
02/22
16:52
02/22/19
16:52
Hot Stocks
Bristol-Myers files proxy statement in connection with proposed Celgene merger »

Bristol-Myers Squibb…

BMY

Bristol-Myers

$50.99

0.84 (1.68%)

CELG

Celgene

$89.15

0.54 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 26

    Feb

  • 28

    Feb

  • 18

    May

  • 20

    May

  • 28

    May

TEN

Tenneco

$36.29

0.76 (2.14%)

16:48
02/22/19
02/22
16:48
02/22/19
16:48
Earnings
Tenneco sees FY19 revenue growth up 4%-5%, consensus $4.65B »

The company expects 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

TEN

Tenneco

$36.29

0.76 (2.14%)

16:46
02/22/19
02/22
16:46
02/22/19
16:46
Earnings
Tenneco reports preliminary Q4 revenue $4.3B, consensus $4.3B »

Sees FY18 EPS "near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

XRX

Xerox

$31.50

0.16 (0.51%)

16:44
02/22/19
02/22
16:44
02/22/19
16:44
Conference/Events
Xerox management to meet with Loop Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TWTR

Twitter

$31.70

0.94 (3.06%)

16:38
02/22/19
02/22
16:38
02/22/19
16:38
Hot Stocks
Twitter board member Evan Williams to step down at end of month »

On February 22, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

ALLY

Ally Financial

$26.95

-0.07 (-0.26%)

16:34
02/22/19
02/22
16:34
02/22/19
16:34
Hot Stocks
Ally Financial CEO sells over 97,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.